Bergenin attenuates neuropathic pain in rats by modulating TRPV1/CGRP signaling and neuroinflammation
Background
Neuropathic pain is a debilitating chronic condition characterized by persistent sensory hypersensitivity, often stemming from nerve damage or dysfunction. Current treatment options, including opioids and gabapentinoids, frequently offer inadequate relief and carry significant side effects. Key to its pathogenesis are neuroinflammation and the activation of TRPV1/CGRP-driven nociceptive pathways, which amplify pain signals. Bergenin, a natural C-glucoside, is recognized for its established anti-inflammatory and antioxidant properties, positioning it as a promising candidate to address these underlying mechanisms and offer a novel therapeutic approach.
Study Design
Researchers induced neuropathic pain in rats using the chronic constriction injury (CCI) model. Animals received either Bergenin (25, 50, and 100 mg/kg, i.p.) or gabapentin (30 mg/kg, i.p.) as a positive control. Nociceptive behaviors were comprehensively evaluated using various tests, including von Frey, paintbrush, pinprick, Hargreaves, acetone spray, and ice floor assays. To assess CNS safety, locomotor activity and motor coordination were also measured. Spinal cord tissue was then analyzed for oxidative stress parameters and the expression levels of TNF-α, IBA1, ICAM1, TRPV1, and CGRP.
Results
The chronic constriction injury (CCI) model successfully induced marked mechanical, thermal, and cold hypersensitivity in rats, alongside elevated oxidative stress and increased expression of neuroinflammatory markers. Bergenin treatment significantly attenuated these pain-related behaviors across all tested doses, demonstrating enhanced efficacy at higher doses. The compound also notably improved the oxido-nitrosative status in the spinal cord. Furthermore, Bergenin downregulated the expression of key inflammatory mediators and pain-related receptors.
Bergenin significantly downregulated
TNF-α,IBA1,ICAM1,TRPV1, andCGRPexpression in spinal cord tissue, indicating broad anti-inflammatory and antinociceptive effects.
Key Findings
- Bergenin significantly attenuated mechanical, thermal, and cold hypersensitivity in CCI-induced neuropathic pain rats.
- Bergenin improved oxido-nitrosative status in the spinal cord of neuropathic rats.
- Bergenin downregulated neuroinflammatory markers
TNF-α,IBA1, andICAM1in spinal cord tissue. - Bergenin reduced the expression of
TRPV1andCGRPin the spinal cord. - Bergenin produced no detectable impairment in locomotor activity or motor coordination.
Why It Matters
This study highlights Bergenin as a promising non-opioid therapeutic strategy for neuropathic pain, offering a multi-targeted approach by simultaneously modulating neuroinflammation, TRPV1/CGRP signaling, and oxidative stress. Unlike many current treatments, Bergenin demonstrated no detectable impairment in locomotor activity or motor coordination, suggesting a favorable safety profile for CNS function. This natural compound could potentially offer a safer, more effective alternative or adjunct to existing neuropathic pain medications like gabapentin, which often have significant side effects. Further preclinical optimization and eventual human trials are crucial to translate these findings into a usable clinical protocol, but the broad mechanistic action is highly encouraging.
bergenin
neuropathic-pain
neuroinflammation
trpv1
cgrp
preclinical-animal